Spiramycin

17 interactions 1 explained in plain English
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Isradipine Flecainide Foscarnet Injection Gemifloxacin Octreotide Octreotide Injection
15 Major 2 Moderate
All (17) Major (15) Moderate (2)

Major

Spiramycin Amitriptyline Elavil Explained An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Spiramycin Arsenic Trioxide Trisenox An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Spiramycin Arsenic Trioxide Injection Trisenox An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Spiramycin Chloroquine Aralen® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Spiramycin Disopyramide Norpace An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Spiramycin Dofetilide Tikosyn An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Spiramycin Dolasetron Anzemet An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Spiramycin Dolasetron Injection Anzemet An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Spiramycin Flecainide Tambocor® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Spiramycin Foscarnet Injection Foscavir An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Spiramycin Gemifloxacin Factive An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Spiramycin Isradipine DynaCirc® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Spiramycin Mefloquine Lariam® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Spiramycin Octreotide Bynfezia An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Spiramycin Octreotide Injection Bynfezia An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details

Moderate

Spiramycin Levodopa Oral Inhalation Inbrija Reduced levodopa plasma concentrations and potential loss of antiparkinsonian effects Details Spiramycin Lixisenatide Injection Adlyxin® Delayed therapeutic effect Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.